Related references
Note: Only part of the references are listed.Bevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
Manju L. Subramanian et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Vascular endothelial growth factor in eye disease
J. S. Penn et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2008)
Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES)
Lihteh Wu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2008)
Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results
C. A. Cleary et al.
EYE (2008)
Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases
K. C. Madhusudhana et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration
S. Aisenbrey et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration
Ratimir Lazic et al.
OPHTHALMOLOGY (2007)
Intravitreal bevacizumab therapy for neovascular age-related macular degeneration:: a pilot study
Maura Lucy Abraham-Marin et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration
M. Vaughn Emerson et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration
Anne E. Fung et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study
Christine Y. Chen et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Vascular endothelial growth factor: Biology and therapeutic applications
Quoc T. Ho et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twenty-four-week results of an uncontrolled open-label clinical study
Andrew A. Moshfeghi et al.
OPHTHALMOLOGY (2006)
The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide
A. E. Fung et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration
Ziad F. Bashshur et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2006)
Short-term safety and efficacy of intravitreal bevacizumab (avastin) for neovascular agerelated macular degeneration
Ryan M. Rich et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
Richard F. Spaide et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
RL Avery et al.
OPHTHALMOLOGY (2006)
Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration
IA Bhutto et al.
EXPERIMENTAL EYE RESEARCH (2006)
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
EWM Ng et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2005)
Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study
S Michels et al.
OPHTHALMOLOGY (2005)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)